Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis

NCT04925557 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Lack of recruitment

Conditions

Secondary-progressive Multiple Sclerosis

Interventions

DRUG: Mayzent
DRUG: Ocrevus

Sponsor

State University of New York at Buffalo